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Abstract 
 
Variations in platelet number, volume and function are largely genetically controlled 
and many loci associated with platelet traits have been identified by genome wide 
association studies (GWAS)
1
. The genome also contains a large number of rare variants, 
of which a tiny fraction underlie the inherited diseases of man. Research over the past 
three decades have led to the discovery of 51 genes harbouring variants responsible 
for inherited platelet disorders (IPDs). However, the majority of patients with an IPD 
still do not receive a molecular diagnosis. Alongside the scientific interest, molecular or 
genetic diagnosis is important for patients. There is increasing recognition that a 
number of IPDs are associated with severe pathologies, including an increased risk of 
malignancy and a definitive diagnosis can inform prognosis and care. 
In this review we give an overview of these disorders grouped according to their effect 
on platelet biology and their clinical characteristics. We also discuss the challenge of 
identifying candidate genes and causal variants therein, how IPDs have been 
historically diagnosed and how this is changing with the introduction of high-
throughput sequencing (HTS). Finally, we describe how integration of large genomic, 
epigenomic and phenotypic datasets, including whole genome sequencing (WGS) data, 
GWAS, epigenomic profiling, protein-protein interaction networks and standardised 
clinical phenotype coding, will drive the discovery of novel mechanisms of disease in 
the near future to improve patient diagnosis and management.  
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Rare Inherited Platelet Disorders  
 
There is marked genetic heterogeneity amongst IPDs and in this section we survey the 
51 genes known to harbour variants responsible for IPDs (henceforth, “IPD genes”), 
classified according to their principal known effect on platelet biology. They encode an 
array of molecules of diverse function, reflecting the complex and tightly regulated 
processes of megakaryopoiesis, platelet formation and platelet function (Fig. 1). For 
some genes, their role in platelet biology is less well defined and this is also discussed. 
Many IPD genes are widely transcribed across blood cell types (Fig. 2) and other 
tissues. Hence, patients with an IPD frequently present with pathologies reaching well 
beyond the blood system
2
 (23 genes marked with *, Fig. 1).  
 
Megakaryopoiesis and Platelet Formation 
Studies in patients with thrombocytopenia have highlighted the important roles of the 
Thpo/Mpl signalling pathway and transcriptional regulation in both early and late 
stages of megakaryopoiesis. Rare variants in THPO and MPL, the genes encoding 
thrombopoietin
3,4 
and its receptor Mpl
5,6 
cause congenital thrombocytopenia and 
seven IPD genes encode transcription factors (GATA1
7,8
, RUNX1
9
, FLI1
10
, ETV6
11
, 
HOXA11
12
, MECOM
13
 and GFI1B
14,15
) expressed in hematopoietic stem and progenitor 
cells (Fig. 2). Rare variants in RBM8A
16
 and ANKRD26
17
 have been shown to affect 
transcription factor binding (of Mecom and Runx1, respectively), altering signalling 
through the Thpo/Mpl pathway and resulting in thrombocytopenia, but their exact role 
in megakaryopoiesis is not yet clear.  
Six IPD genes regulate the megakaryocyte cytoskeleton and the principal effect of 
deleterious variants is macrothrombocytopenia due to aberrant proplatelet formation 
(variants in MYH9
18
, ACTN1
19
, FLNA
20
, TUBB1
21
, DIAPH1
22
). Causal variants in the 
Wiskott-Aldrich Syndrome gene WAS also lead to defective proplatelet formation 
alongside neutropenia and eczema but, in contrast to other cytoskeletal disorders, the 
platelets are small
23,24
. So far six genes encoding proteins that primarily influence 
granule formation, trafficking or secretion (NBEAL2
25-27
, NBEA
28
, VPS33B
29
, VIPAS39
30
, 
STXBP2
31,32
, LYST
33
) and nine genes that cause Hermansky Pudlak Syndrome (HPS), a δ-
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granule platelet disorder (HPS1, AP3B1, HPS3, HPS4, HPS5, HPS6, DTNBP1, BLOC1S3, 
BLOC1S6
34-41
) have been identified. 
Defects in transmembrane glycoprotein (GP) signalling pathways can lead to abnormal 
platelet function and thrombocytopenia with giant platelets through abnormal 
proplatelet formation (GP1BA, GP1BB, GP9
42,43
) and thrombasthenia only (ITGA2B, 
ITGB3
44,45
). Gain-of-function (GOF) variants in GP1BA can cause enhanced binding to 
Von Willebrand Factor (Vwf) leading to “platelet-type” Von Willebrands Disease 
(VWD)
46
, a phenocopy of Type 2B VWD, a disorder caused by GOF variants in VWF 
affecting the function of its A1 domain
47
. In both cases premature interaction between 
Gp1ba and the Vwf A1 domain results in bleeding characterised by thrombocytopenia 
and a loss of high molecular weight Vwf multimers. DNA analysis is generally required 
to distinguish between these two disorders.   
The role of some IPD genes in megakaryopoiesis and proplatelet formation is less well 
defined. The recent discovery of a GOF variant in SRC causing abnormal 
megakaryopoiesis and thrombocytopenia has cemented the central role of this 
universal tyrosine kinase in a variety of megakaryocyte signalling pathways and 
podosome formation
48
; CYCS is expected to play a role in apoptosis
49
; certain GOF 
variants in STIM1 (causal of Störmorken syndrome) result in thrombocytopenia with 
abnormal platelet function and bleeding, whereas loss-of-function (LOF) variants in 
STIM1 cause an autoimmune thrombocytopenia. LOF variants in ORAI1 have been 
described in a mild Störmorken-like syndrome but the platelet defects are not well 
established. Both Orai1 and Stim1 are involved in calcium homeostasis and IPD-causing 
variants consequently affect platelet signalling but further research is required into 
their role in platelet formation
50-52
. Novel missense variants were recently identified in 
SLFN14 in four unrelated pedigrees with moderate thrombocytopenia and platelet 
secretion defects. Though the mechanism is not clear, a defect in platelet formation 
was observed
53,54
. Finally, Quebec platelet disorder, so far confined to French-
Canadians, is caused by a tandem duplication in PLAU, leading to overexpression of 
urokinase and is characterised by thrombocytopenia, degradation of α-granule 
contents with normal granule structure, decreased aggregation in response to 
epinephrine and late onset bleeding
55
. 
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Platelet Function 
There are 14 IPD genes primarily affecting various aspects of platelet function. Six 
genes encode GPs which function as receptors for the hemostatically important ligands 
Vwf (GP1BA, GP1BB, GP9 gene defects causing Bernard Soulier syndrome {BSS})
43
, 
fibrinogen (ITGA2, ITGB3 gene defects causing Glanzmann Thrombasthenia {GT})
45
 and 
collagen (GP6)
56
. The typical mode of inheritance for GT is autosomal recessive with 
LOF variants of ITGA2B or ITGB3. This classical thrombasthenia is reviewed extensively 
elsewhere
45
, but it is worth noting that, again, rare and dominant GOF variants in 
ITGB3 have also been described, leading to enhanced fibrinogen binding combined 
with bleeding
57
 and a mild thrombocytopenia exacerbated during pregnancy but 
without bleeding
58
. Mutations in FERMT3 affect integrin inside-out signalling causing a 
GT-like platelet phenotype with bleeding and associated with a type III leukocyte 
adhesion disorder
59
. A homozygous variant in RASGRP2 was discovered as a cause of 
another mild GT-like platelet phenotype in a consanguineous pedigree. RASGRP2 
encodes for a guanidine exchange factor that regulates Rap1b activation and 
consequently has a major effect on αIIbβ3 (encoded by ITGA2B, ITGB3) signalling in 
platelets
60
. 
G-protein coupled receptors (GPCRs) are another main type of multispan 
transmembrane receptors and signalling defects due to variants in P2YR12
61
 and 
TBXA2R
62
 (encoding the GPCRs for ADP and thromboxane
 
respectively) or their 
downstream effectors (TBXAS1
63
, PLA2G4A
64
) have been linked to IPDs. Scott 
syndrome does not fall into the aforementioned categories and is caused by autosomal 
recessive variants in ANO6, which encodes a multispan transmembrane protein 
involved in phospholipid scrambling
65
. Platelets from these cases cannot properly 
express phosphatidylserine on their surface, which leads to defective coagulation.   
 
Current Approaches to Diagnosis  
IPD diagnosis is straightforward in the major platelet function disorders such as BSS 
and GT, which often present with severe bleeding symptoms early in life and are easily 
recognised by the pattern of platelet aggregation defects
45,66
. This is often 
supplemented by assessment of the storage pool either directly by nucleotide assay or 
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lumi-aggregometry. In some IPDs, the platelet function defect and impaired hemostasis 
are part of well-defined syndromes, e.g. Chediak Higashi Syndrome (CHS) and HPS, 
where the platelet δ-granule defect is typically associated with immune deficiency or 
ocular albinism, respectively. The presence of syndromic features can help in 
recognition and diagnosis but diagnosis remains challenging for the majority of IPDs, 
which often have a mild platelet phenotype and are clinically heterogeneous. Diagnosis 
is further complicated by the fact that for many IPDs, the platelet count is within 
normal ranges and the disorder may only become apparent after a hemostatic 
challenge or if cases present with accompanying pathologies in other organ systems, 
including malignancies
67
.  
Establishing a conclusive molecular diagnosis is the bedrock of good hematological 
practice because it informs optimal treatment and can provide clarity about disease 
progression. For IPDs, this is particularly important for the severe cases and those 
associated with early onset clinical pathologies such as myelofibrosis, lung fibrosis, 
renal insufficiency and malignancy. Thrombocytopenias caused by variants in RUNX1, 
ETV6 and ANKRD26
9,68,69
 are associated with increased risk of myeloid malignancy 
while for WAS and amegakaryocytic thrombocytopenia caused by MPL variants, 
treatment by allogeneic hematopoietic stem cell transplant or gene therapy may 
require consideration. Moreover, genetic counselling can be provided if the diagnosis is 
confirmed at the DNA level
70-72
. Current guidelines favour a tiered approach to IPD 
diagnosis. DNA analysis by Sanger sequencing is at the fourth and final tier and often 
not applied because of its limited availability and costs
66
. Moreover, it is used primarily 
to confirm an already clinically suspected genetic diagnosis and targets only a single or 
small group of genes. In the majority of IPDs, a single candidate gene is not readily 
apparent from standard laboratory tests. Consequently, a molecular diagnosis is given 
in only a minority of patients and even when a genetic defect is identified, the number 
of independent cases remains small for the majority of IPDs
73,74
. Fewer than five 
unrelated probands have been identified for IPD genes P2Y12R
75
, GP6
76,77
, TBXA2R
78
, 
PLAU, ANO6
79
, which all were identified before the era of HTS and there is a paucity of 
larger case series for individual IPD genes with the exception of ACTN1
80
 and 
ANKRD26
81
.   
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This lack of genetic diagnosis not only hampers our ability to provide accurate 
information on prognosis and optimal management, but the small case numbers also 
impact on our ability to interpret the pathogenicity of particular variants. The advent of 
HTS is set to change this. In this issue of Blood, the ThromboGenomics consortium 
reports on a targeted HTS panel of 76 genes (63 genes in the panel reported in their 
publication and a further 13 genes added in the currently available version) covering 
the inherited bleeding, thrombotic and platelet disorders (BPDs), bringing an 
affordable molecular diagnosis within reach
82
. The application of HTS will simplify the 
diagnostic process and reduce delay, as we discuss below. 
IPD Gene Discovery to Date  
Until recently, the majority of IPD genes have been discovered by candidate gene and 
linkage studies. These approaches resulted in the identification of 36 IPD genes by 
2010, when HTS became available (Fig. 3). In 2011 three groups reported on NBEAL2 
being the causal gene for Gray Platelet syndrome (GPS)
25-27
 and two of these 
discoveries were made possible by HTS. In the past five years 14 additional IPD genes 
have been identified, 11 by applying HTS (Fig. 3). Thrombocytopenia with absent radii 
(TAR) is an example of a syndrome for which the genetic roots remained elusive 
despite being clinically well defined for over two decades. It has a thus far unique 
genetic architecture typically involving a micro-deletion on one haplotype and a low-
frequency regulatory variant on the other haplotype of RBM8A. The most commonly 
implicated regulatory variant results in reduced binding of the transcription factor 
Mecom leading to an insufficiency of the protein Y14 in megakaryocytes, causing 
thrombocytopenia
16
. In addition, WES was also instrumental in discovering variants in 
GFI1B responsible for a GPS-like syndrome
14,15
; ACTN1
19
, ETV6
11
, STIM1
50
, DIAPH1
22
, 
SRC
48
, SLFN14
53
 and MECOM
13
 for inherited thrombocytopenias; and RASGRP2 for GT-
like disease
60
.  
The results of the rare diseases pilot phase of the 100,000 Genomes Project
83
 indicate 
that a large number of IPD genes remain to be discovered. Genome sequencing results 
of the DNA samples of hundreds of probands with uncharacterised BPDs, analysed 
using assigned Human Phenotype Ontology (HPO) terms
2
 have helped identify 
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pathogenic variants in known IPD genes in almost 20% of cases. New clustering 
algorithms to group cases with similar phenotypes
48,84
, have been used to identify two 
novel IPD genes (DIAPH1 and SRC)
22,48
 and several putative ones. This suggests that the 
majority of cases either harbour pathogenic variants in unknown genes or regulatory 
regions or are the result of a digenic mode of inheritance. 
The lack of gene discoveries on a global scale for δ-granule Storage Pool Disease (δ-
SPD) is a case in point. The true prevalence of δ-SPD is unclear, as the definition is not 
always consistent between studies, but defects in granule release are relatively 
frequent amongst the mild IPDs
73,85
. The greatest diagnostic success for δ-SPD has 
been in the multi-system syndromes such as CHS and HPS but most patients with non-
syndromic δ-SPD remain undiagnosed
86
. In on-going large-scale HTS projects such as 
GAPP
87,88
 and BRIDGE-BPD
2,22,48
, the lack of gene discovery for δ-SPD, even in these 
large patient cohorts, highlights a need to analyse the non-coding regulatory regions of 
the genome via WGS, whilst also exploring novel methods of data analysis and 
integration. We discuss such methods in more detail in the final section. 
Assigning Pathogenicity to Novel Variants: Use of Public Databases   
With the advent of HTS it has become possible to survey the exonic fraction of large 
numbers of genomes for variants by WES. Exomes comprise ~2% of the genome (~64 
Mb) while current WGS captures 98.3% of the 3.2 billion bases of the genome at a 
minimum of 15x coverage. Information about pathogenic and likely pathogenic 
variants is maintained in databases but until recently it was not possible to verify their 
allele frequencies in the general population. Several initiatives such as the 1000 
Genomes
89
 and UK10K
90
 projects and initiatives to aggregate results from many smaller 
WES projects, as achieved by the Exome Aggregation Consortium (ExAC)
91
, have 
provided information on exonic variants observed in more than 71,000 individuals of 
mainly Caucasoid ancestry. This catalogue has made an immense contribution to 
improving the accuracy of assignment of pathogenicity to DNA variants observed in IPD 
cases. There is still a relative paucity of sequencing data from individuals of other 
ethnicities. Consequently, a larger number of variants absent from control samples is 
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observed in their DNA, making it harder to distinguish variants which are relatively 
common in particular populations from variants responsible for disease. 
HTS has also made possible large-scale WGS projects such as the 100,000 Genomes 
Project
83
 which are complemented by GWAS in large population cohorts such as the UK 
Biobank of 500,000 healthy individuals
92
. Both projects link genotypes with health and 
social care records and will lead to a better understanding of the relationship between 
variants and diseases. In particular, they will allow more accurate assignment of 
pathogenicity to rare variants underlying the thousands of inherited diseases. Single 
nucleotide variants (SNV) can be called accurately by WES but calling of short 
insertions and deletions and especially of copy number and structural variants is more 
challenging. Here WGS can achieve far greater sensitivity and specificity than WES. 
WGS will therefore further improve the accuracy of frequencies for all classes of 
variants in databases, make it easier to discover the genetic determinants of rare 
inherited diseases and also open up opportunities to explore the non-coding regulatory 
part of the genome. 
Germline variants are inevitable consequences of meiosis and DNA repair, and 
accumulate over generations. Given the existence of many non-pathogenic variants in 
any individual’s genome, the main challenge faced by researchers when interpreting 
HTS data of an IPD case is determining which variants are causing the disorder. The 
correct identification of novel causal variants critically depends on their allele 
frequency in relevant control samples
93
. Additionally, studies are required to uncover 
the function of novel genes and the consequences of candidate rare variants. It has 
been shown that specific GOF variants in DIAPH1 and SRC can cause a defect in 
megakaryopoiesis while this is not expected of LOF variants
22,48
. Similar observations 
can be made for SFLN14 were all variants are located in the ATPase-AAA-4 domain 
while rare variants outside this domain seem not to result in an IPD
54
. 
There are publicly accessible databases like ClinVar
94
 and DECIPHER
95
, Exome variant 
server
96
 and access-for-a-fee databases like Human Gene Mutation Database (HGMD)
97
 
that record disease-associated variants. HGMD maintains a catalogue of high-
penetrance variants derived from the literature
97
. None of these databases are 100% 
accurate: For example, 539 rare variants denoted disease-causing in HGMD were 
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observed in the 1000 Genomes Project at a frequency above 1%
98
 and 140 variants 
labelled as causing BPDs showed a frequency in ExAC above 0.1%, yet the evidence 
supporting a claim to pathogenicity was deemed insufficient for all but four variants
82
.     
In conclusion, large-scale population sequencing projects have greatly enhanced our 
ability to interpret the pathogenicity of potential candidate IPD-causing variants, but 
there are pitfalls: any rare variant must be interpreted in the context of the ethnicity of 
the individual and great care must be taken not to over-interpret the pathogenicity of 
novel variants absent from control datasets, even in established IPD genes, without 
back-up from functional studies or observation of the same variant in several unrelated 
cases with similar phenotypes. 
The Future of IPD Gene Discovery  
HTS will undoubtedly assist the discovery of variants causing IPDs in many new genes 
over the next decade but genomic sequencing alone cannot explain the mechanisms 
underlying the relationship between genotype and phenotype in cases with an 
apparent inherited disorder
99
. In order to ascertain the functional consequences of 
rare variants, it is essential that knowledge of phenotypes and pathways is integrated 
systematically within a frame of reference similar to that of the human genome
100
.
 
Data from a wide variety of sources, including GWAS, Online Medelian Inheritance in 
Man (OMIM) and mouse genome databases can be used to annotate candidate 
regions, better understand individual proteins and their roles in pathways relevant to 
megakaryopoiesis and platelet formation. Identification of the regulatory DNA 
elements has become feasible thanks to the results from projects like ENCODE
101
, 
Roadmap
102
 and Blueprint
103,
 coordinated by the International Human Epigenome 
Consortium (IHEC). Integration of different layers of information, including methylation 
and histone modification states, expression quantitative trait loci data, transcriptomics 
and proteomics, requires the development of new statistical methods. Some insights 
on how this richness of information can aid the discovery of novel causes of disease 
will be discussed in the following sections. 
Human Phenotype Ontology  
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To maintain power of gene discovery, cases sharing similar clinical and laboratory 
phenotypes need to be identified and new methods have been sought to cluster 
similar cases in the ever-growing cohorts undergoing genome sequencing. One of the 
widely used phenotype annotation standard for rare diseases is the HPO terms 
system
104
. HPO coding is used by the Deciphering of Developmental Disorders
105
 and 
100,000 Genomes Projects and so far 1,247 probands with BPDs have been HPO 
coded
2
. This revealed the presence of non-hematological pathologies in 60% of cases, 
particularly in the central nervous (e.g. autism spectrum disorder), skeletal (e.g. 
osteoporosis) and immune systems
2
. This insight into the more complex spectrum of 
pathologies in IPD cases is important for the provision of care, which often warrants a 
multi-disciplinary approach. Additionally, standardised phenotyping by means of HPO 
terms is critical for IPD gene discovery across large collections of cases. Indeed, 
genome sequencing combined with HPO coding supported the identification of the 
DIAPH1 variant in two unrelated pedigrees with similar phenotype terms 
‘Thrombocytopenia’ and ‘Deafness’
22
. It also allowed integration with existing 
phenotype databases, such as the one for mouse phenotype ontology (MPO) terms, 
which aided the discovery of the SRC variant because cases and knockout mice shared 
HPO terms
48
. These discoveries are critically dependent on new statistical methods 
which exploit the power of HPO-based patient coding together with genotypes 
obtained by sequencing
84,106,107
 
In order to discover which genes are pertinent to the remaining IPDs, screening of large 
case collections will be essential. The small number of reported independent cases in 
the majority of IPDs and the lack of discovery in SPD to date indicates that extremely 
large collections are needed to bring together adequate numbers of unrelated index 
cases with a shared genetic basis. International collaboration is therefore warranted 
and will also bring together expertise about the clinical evolution of disease for each of 
the IPD genes. This collaborative approach will provide the platform to evaluate 
existing and new interventions to gather evidence for the best approach to treatment. 
That such international approaches can be successful has been demonstrated by the 
BRIDGE-BPD and ThromboGenomics consortium efforts reported in this issue
22,82
 and 
in other journals
48,84
. 
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The Non-coding Regulatory Space 
The genome comprises 3.2 billion base pairs, 98% of which do not form part of a 
recognised gene. The non-exonic portion of the genome is largely regulatory in nature 
but the landscape of regulatory elements differs between cell types. The 
aforementioned IHEC initiatives have generated accurate maps of regulatory elements. 
The discoveries that specific heterozygous GOF variants in the 5’UTR of ANKRD26 
cause thrombocytopenia
108
 and that the vast majority of TAR syndrome cases of 
Northern European ancestry are due to compound inheritance of one RBM8A null 
allele and a low-frequency SNV in its 5’UTR
16
 indicate that cell-specific knowledge of 
the regulatory space may help to identify novel mechanisms of disease in future. It is 
likely that similar non-coding regulatory variants in known or novel IPD genes remain 
to be discovered and integrating IHEC reference epigenome maps with the catalogue 
of blood cell-type-specific transcript isoform usage can help interpret the consequence 
of non-coding DNA variants observed in IPD cases
103
. The exploration of the non-coding 
portion of the genome for variants causal of IPDs requires many parallel approaches 
recognising the complexity of the regulatory networks at play. For example the cell-
specific role of non-coding RNAs has been recently highlighted
109
. Finally the rapidly 
accumulating ChIP-seq data defining the binding sites for transcription factors in 
different cell types, including data generated in megakaryocytes will also be of value
110
.  
GWAS for Platelet Traits 
Meta-analysis of GWAS for blood cell traits has led to the discovery of nearly 200 
common SNVs exerting small effects on blood cell indices
111
. These variants mark 
known and new genomic regions important for hematopoiesis and blood cell survival. 
With GWAS being performed on ever-larger population samples such as the UK 
Biobank and Million Veteran cohorts, the number of associated SNVs is predicted to 
rise substantially, with increasing numbers of rare variants with larger effect sizes 
being revealed. A picture is therefore emerging of hundreds of genes identified by 
GWAS controlling the life cycle of platelets and the maximum effect sizes of variants in 
these genes on platelet traits are inversely correlated with their MAFs due to selection. 
This assumption is illustrated by recent observations in TUBB1. The common non-
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coding SNV rs4812048 was linked with an effect on platelet volume by GWAS
1
 and rare 
non-synonymous SNVs have since been reported as a cause of 
macrothrombocytopenia in man
21,112-114
. This suggests that integrating knowledge 
about GWAS loci affecting platelet indices alongside genome sequencing data of 
collections of patients with IPDs of unknown molecular etiology may reveal novel 
candidate genes.  
Protein-protein Networks 
Knowledge about the molecules and pathways underlying megakaryopoiesis and the 
formation of platelets is rapidly expanding. Bringing knowledge gathered from 
GWAS
111
 and inherited BPDs  (the 76 BPD genes reported by Simeoni et al, this issue 
82
) 
together with information about genes identified by ChIP-seq
110
 we defined 200 
unique genes deemed important for these processes (Fig. 4B). The proteins encoded 
by these “seed genes” were used as baits to retrieve their first-order interactors from 
the Reactome and IntAct databases using previously reported informatics 
approaches
1,115
. This information was displayed as a protein-protein interaction 
network (PPIN) consisting of 1,684 nodes (proteins) connected by 5,360 biochemical 
interactions (edges) using the Cytoscape application (Fig. 4A). To make this PPIN, which 
encompasses the knowledge from thousands of publications available to the scientific 
and medical communities in a format allowing its unrestricted use, we have made a 
Cytoscape file available for download (Supplemental data). For example, it can be used 
to resolve IPDs with digenic roots as illustrated by observations in TBXA2R: four reports 
describe LOF variants of TBXA2R in patients with platelet defects as a dominant finding. 
Although heterozygosity for the TBXA2R variants correlated with the platelet defect in 
these carriers, there was no association with bleeding problems. It was noted that a 
potential second genetic factor would be required to cause bleeding. Two sub-
networks (Fig. 4C, D) of proteins important for the signalling events downstream of the 
thromboxane receptor (Fig. 4C) and for the synthesis of thromboxane (Fig. 4D) may 
highlight potential candidates for this second gene
78,116-118
. Indeed we observed a case 
with severe bleeding and a LOF variant in TBXA2R (Fig. 4C) and a second putative 
causal variant was identified in PTGS1, which encodes for Cyclooxygenase-1
119
. 
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Conclusion 
HTS has enabled the discovery of many novel IPD genes in the past five years and this 
new knowledge can be rapidly integrated in diagnostic platforms like the 
ThromboGenomics HTS test, which will simplify and hasten diagnosis of IPDs. There is 
however still an immense challenge to resolve the genetic basis of the remaining IPDs 
and to gather better evidence for the best treatments. This can only happen through 
international collaboration and knowledge sharing. We must seek permission from 
patients and their families to share their genotype and phenotype data and invest in 
standardized phenotyping using internationally agreed terms like those of the HPO 
system. There is also an obligation for the research and clinical communities to pursue 
the development of informatics environments for the safe sharing of anonymized and 
linked-anonymized data. WGS combined with emerging data from GWAS, ChIP-seq, 
proteomics and mouse knock-out studies amongst others will also help explore the 
non-coding regulatory space and identify novel candidate IPD genes and variants.  
Finally, as there are many potential pitfalls when interpreting the role of novel rare 
variants, it is important to apply rigorous standards when assigning pathogenicity. 
Providing a molecular diagnosis to patients is highly desirable but making incorrect 
assumptions about variants could be harmful. 
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Figure Legends 
 
Figure 1: The 51 genes underlying Inherited Platelet Disorders. 
 The cartoon depicts the process of megakaryopoiesis and platelet formation. Each 
of the 51 known inherited platelet disorder (IPD) genes are indicated and 
categorised according to their effect on megakaryocyte and platelet biology. IPDs 
typically associated with phenotypes outside of the blood system are indicated by *; 
HSC, hematopoietic stem cell. 
 
Figure 2: Expression levels of 51 genes underlying Inherited Platelet Disorders 
across hematopoietic stem and progenitor cells. 
High relative expression is shown in red and low relative expression in blue. The 
expression of each gene is normalized compared to a mean expression of zero across 
all the samples. Genes are ordered and colour-coded according to their predicted 
effect on platelet biology (as in Fig. 1). Information about the levels of transcripts for 
the 51 genes determined by RNA-seq was retrieved from Chen et al
103
. HSC, 
hematopoietic stem cell; MPP, multipotent progenitor; CLP, common lymphoid 
progenitor; CMP, common myeloid progenitor; GMP, granulocyte-monocyte 
progenitor; MEP, megakaryocyte-erythrocyte precursor; EB, erythroblast; MK, 
megakaryocyte.  
 
Figure 3: Genomic location of the 51 genes underlying Inherited Platelet Disorders. 
Circos diagram
120
 illustrating the location of known IPD genes across human 
chromosomes. Track 1: Cytoband with chromosome name with centromeres in blue. 
Track 2: Genomic location of 51 established inherited platelet disorder (IPD) genes 
and the year in which variants in the gene were first identified as a cause of IPD in 
humans in brackets. Gene names in red represent genes identified by high 
throughput sequencing. Track 3: Log
10
 of the number of amino acids encoded by the 
reference CCDS transcript. Log
10
 
scale is indicated at 12 o’clock. Track 4: Log
10
 
of the 
number of rare variants predicted to affect amino acid sequence observed in 6,390 
individuals enrolled to the NIHR BioResource – Rare Diseases; Log
10
 
scale is indicated 
at 12 o’clock.  
 
Figure 4: Protein-protein interaction network reflecting the molecules and 
pathways implicated in megakaryopoiesis, the formation of platelets, thrombosis 
and hemostasis. 
A. Protein-protein interaction network (PPIN) of 1,684 nodes (proteins) connected 
by 5,360 edges (biochemical reactions). The 1,517 first-order interacting nodes and 
all but 24 of the 5,360 edges were obtained from the Reactome (n=3,625) and IntAct 
(n=1,711) databases. The 24 edges were added on basis of manual literature 
curation. The 200 baits are colored as per the Venn diagram (B) except for the eight 
baits present in more than one category, which are pink and the eight prototype 
proteins involved in the synthesis of thromboxane and signalling via the 
thromboxane-thromboxane receptor (Tbxa2r) pathway. The Venn diagram shows 
the three gene sets in ochre, blue and purple for the ThromboGenomics HTS test 
platform gene set
82
, the platelet volume and count GWAS gene set
1
 or the gene set 
identified by ChIP-seq in human megakaryocytes and showing binding of all five 
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transcription factors (Fli1, Gata1, Gata2, Runx1, Tal1) at their promoter
110
, 
respectively. C and D. Sub-networks retrieved from the PPIN in (A). C. A sub-network 
of 156 nodes and 874 edges obtained by retrieving the first order interactors of 
Tbxa2r, the receptor for thromboxane. D. A sub-network of 26 nodes and 42 edges 
involved in the synthesis of thromboxane and obtained by selecting the first order 
interactors of Tbxas1 (Thromboxane synthase 1) and Pla2g4a (Phospholipase A2). 
The red nodes in C and D are a set of prototype proteins related with thromboxane 
synthesis and signalling and the other colored nodes are baits. The surface area of 
the red colored nodes in A and all colored nodes in C and D equate with their 
transcript level determined by sequencing of RNA from human megakaryocytes 
(data retrieved from Chen et al)
103
. An interactive version of the network, containing 
gene expression levels and other annotation features is available for download in  
Cytoscape format from Supplemental data. 
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Glossary of Terms 
 
Inherited Platelet Disorder (IPD): Any genetic abnormality of platelet number, 
morphology or function in humans 
 
IPD Gene:  A gene in which a DNA variant has been shown to cause an IPD in humans 
 
Bleeding, Thrombotic and Platelet Disorders (BPD): Term used by the NIHR 
BioResource and the ThromboGenomics consortium to describe cases with genetic 
variants leading to a tendency to bleed abnormally, or a tendency to abnormal 
thrombosis or an abnormality of the count, volume, morphology or function of 
platelets. 
 
High-Throughput Sequencing (HTS): Term encompassing a variety of modern 
techniques, which allow the sequencing of DNA and RNA more quickly and cheaply 
than traditional Sanger sequencing (also referred to as next-generation sequencing). 
 
Minor Allele Frequency (MAF): The frequency at which the least common allele at a 
particular variant position occurs in a population. 
 
Whole Exome Sequencing (WES): The sequencing by HTS of the coding portion of the 
genome comprising ~65 million bases. 
 
Whole Genome Sequencing (WGS): The sequencing by HTS of the entire genome 
comprising ~3.2 billion bases.  
 
Single Nucleotide Variant (SNV): A single base pair alteration in a DNA sequence 
compared to the reference genome for a particular species. A SNV does not necessarily 
alter the function of a gene. SNVs can be common (MAF>5%), low frequency (MAF 
between 1% and 5%) or rare (MAF<1%). 
 
Loss of Function (LOF): A variant allele causing the complete or partial absence of 
normal gene function compared to the wild-type allele. 
 
Gain of Function (GOF): A variant allele causing a gain of normal gene function 
compared to the wild-type allele. 
 
5-prime untranslated region (5’UTR): The section of the message RNA (mRNA) 
upstream from the start codon (where translation of mRNA starts). The 5’UTR is 
important in regulating translation. 
 
ChIP-seq (Chromatin immunoprecipitation combined with HTS): A powerful method 
for identifying modification of DNA-associated proteins like histones or used for 
mapping the binding sites of proteins like transcription factors; the method is used 
extensively to enhance the functional annotation of the non-coding portion of the 
genome. 
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Genome Wide Association Study (GWAS): A study comparing the frequencies of 
millions of SNVs across thousands of people with and without a particular disease or 
assessing the effect of these SNVs on a quantitative trait. This type of study explores 
the genome in a hypothesis-free approach for variants that confer a risk for a particular 
disease or are exerting an effect on the value of a certain trait.   
 
Protein-protein interaction network (PPIN): A representation of physical contacts 
established between proteins. PPINs can encompass knowledge on biochemical 
pathways derived from thousands of experiments and may be represented graphically 
in a network diagram.  
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